Navigating the Delaware R&D Tax Credit: A Deep Dive into the 15-Year Carryforward Period and Refundability Paradox

I. Executive Summary: Reconciling Carryforward and Refundability

The Carryforward Period (15 Years) sets the maximum timeframe for utilizing unused Delaware R&D tax credits against future state income tax liabilities. However, the current law mandates that unused credits be paid as a cash refund, minimizing the need for the carryforward mechanism for recently generated credits.

Detailed Nuanced Overview of the Disposition Conflict

The State of Delaware maintains one of the most proactive and financially attractive Research and Development (R&D) tax incentive programs in the United States, primarily due to the unique feature of its tax credit: full refundability.1 This refundability status fundamentally changes the operational utility of the 15-year carryforward period (CFP) frequently referenced in guidance and statutes.2

The statutory directive regarding the disposition of excess credits is found in Delaware Code, Title 30, Chapter 20, Subchapter VIII, $\S 2070(c)$. This subsection explicitly governs how the Delaware Division of Revenue (DOR) must handle a credit amount that exceeds a taxpayer’s liability for the taxable year: “If the taxpayer cannot use the entire amount of the approved research and development tax credit, such unused credit shall be paid to it in the nature of a tax refund“.5 The use of the term “shall” imposes a mandatory requirement on the state, eliminating discretion and guaranteeing the cash realization of the credit.

For R&D credits generated in current and recent tax years (those beginning after December 31, 2016), this mandatory cash refund effectively supersedes the practical application of the 15-year carryforward.7 If an approved credit is immediately liquidated as cash, there is no unused balance remaining to be carried forward to subsequent tax years. The 15-year CFP is not explicitly repealed, but its operational necessity is nullified for credits generated under the post-2017 refundable regime. This creates an administrative and legal complexity, as many professional advisory resources continue to reference the 15-year carryforward as a standard attribute of the credit.2 This persistent reference arises because the CFP is maintained in the state’s tax architecture to define the maximum expiration date for any deferred tax asset, including any potentially non-refundable credits generated prior to the 2017 legislative change or credits from other non-refundable state incentive programs.

The contemporary meaning of the 15-year CFP is therefore dual: it defines the legal limit for tracking a deferred tax asset (a historical function) and establishes the maximum duration for which a credit could exist, should future legislative changes remove the refundability provision. For current tax planning, businesses benefit from the liquidity provided by the mandatory refund, diminishing the need for the complex financial tracking over the full 15-year term associated with non-refundable credits.

II. Foundational Elements of the Delaware R&D Tax Credit

A. Statutory Basis and Integration with Federal Law

The Delaware R&D tax credit is a significant state incentive designed to promote innovation and economic growth within the state. It is governed by the Delaware Code Annotated, Title 30, Chapter 20, Subchapter VIII, specifically $\S\S 2070$ through $2075$.3

The qualification criteria for the state credit are inextricably linked to federal definitions. Delaware law stipulates that “Delaware qualified research and development” must meet the definition of “qualified research” as defined in $\S 41(d)$ of the Internal Revenue Code (IRC).8 This means that any research and development activity conducted within Delaware that qualifies for the federal R&D tax credit automatically meets the state’s eligibility standards.1 This conformity ensures predictability for taxpayers, as the rigorous documentation and definition standards established by the IRS for federal Form 6765 serve as the foundation for the state claim.4

The credit is widely available across business structures. Eligible entities include C-Corporations, S-Corporations, Partnerships, and Limited Liability Companies (LLCs).2 For flow-through entities, such as S-Corporations and Partnerships, the credit is allocated to the partners or shareholders in accordance with the provisions outlined in IRC $\S 41(f)(2)(B)$.6 The recipient owners then utilize the allocated credit against their personal Delaware income tax liability.

B. Calculation Frameworks and Enhanced Rates

Taxpayers are required to make an annual election, which may be independent of the method used for the federal credit, to determine the value of their Delaware R&D credit.6 The two primary calculation methods available are:

1. Excess Qualified Research Expense (QRE) Method: This traditional method calculates the credit based on the excess of current-year Delaware QREs over a state-specific base amount.3 The fixed-base percentage is determined by the ratio of Delaware QREs to gross receipts for the four preceding years.3

• Standard Businesses (Gross Receipts Exceeding $20 Million): The credit rate is 10% of the excess QREs.6
• Small Businesses (Average Annual Gross Receipts of $20 Million or Less): The credit rate is doubled to 20% of the excess QREs.2

1. Alternative Simplified Credit (ASC) Method: This method links the state credit to the federal Alternative Simplified Credit calculation under IRC $\S 41(c)(5)$, simplifying the base calculation and often proving beneficial for businesses with fluctuating QREs.2

• Standard Businesses: The credit is 50% of Delaware’s apportioned share of the federal ASC.2
• Small Businesses: The credit is 100% of Delaware’s apportioned share of the federal ASC.2

Delaware’s apportioned share of the federal ASC is determined by multiplying the total federal ASC amount by a fraction, the numerator of which is the taxpayer’s Delaware QREs for the taxable year, and the denominator is the taxpayer’s total QREs for the taxable year.6 This ensures the state only grants credit for the research activities physically conducted and sourced within Delaware.3

The enhanced incentives for small businesses (20% excess QRE rate or 100% of the apportioned ASC) combined with the full refundability feature creates a powerful incentive structure highly favorable to emerging companies, such as pre-revenue biotech firms or growth-stage technology startups.1 This structure transforms the typical R&D credit, which is often a deferred tax asset, into immediate operating capital. By providing the benefit as immediate cash flow rather than relying on future profits to utilize a carryforward balance, the state significantly mitigates the financial planning risk associated with long-term credit deferral, positioning Delaware as a unique and attractive jurisdiction for innovative industries.2

III. The Statutory Conflict: Refundability vs. Carryforward

The concept of a 15-year carryforward period cannot be fully understood without analyzing the historical context of the Delaware R&D tax credit and the specific legislative amendments that introduced mandatory refundability.

A. The Legal Evolution: The Pre-2017 Necessity of Carryforward

Prior to the legislative changes that became effective for tax years beginning after December 31, 2016, the Delaware R&D tax credit was structured as a non-refundable credit, making the carryforward mechanism indispensable.7

Before this overhaul, the credit was subject to two major limitations:

1. Liability Limitation: The maximum credit a taxpayer could utilize in a single taxable year was limited to 50% of the taxpayer’s qualified tax liability.4
2. Statewide Cap: The state imposed an aggregate annual cap on the total amount of credits awarded statewide, initially set at $5 million. If the total approved credits exceeded this cap, the credits were prorated among all applicants.2

Under this former regime, if a company’s approved credit exceeded the 50% liability limit, or if the company had insufficient tax liability (e.g., due to losses), the unused portion was strictly non-refundable.4 In such instances, the unused credit was required to be carried forward for a maximum period of 15 years to offset future tax liabilities.2 This 15-year window served as the legal life span of the deferred tax asset.

B. The 2017 Legislative Overhaul and the Refund Mandate

The legal framework changed dramatically with the enactment of legislation (specifically, 80 Del. Laws, c. 207) that became effective for the 2017 tax year.7 This overhaul was designed to significantly enhance the credit’s competitiveness:

• Elimination of Limitations: The legislation eliminated both the 50% limitation on tax liability and the statewide $5 million annual cap.2 Companies now receive 100% of their calculated, expected credit.1
• Mandatory Refundability: The most impactful change was making the credit fully refundable.2 As codified in $\S 2070(c)$, any credit amount remaining after application against the current year’s qualified tax liability must be paid to the taxpayer as a tax refund.5

The critical implication of this mandatory refundability is that, for credits generated post-2017, the credit is utilized immediately—either by offsetting current taxes or by conversion to cash. This disposition liquidates the unused portion, legally removing the necessity of relying on the 15-year CFP for utilization. Had the statute used language such as “may be paid as a refund or carried forward,” the taxpayer would have an elective choice. Since the code uses “shall,” the refund is the non-negotiable legal outcome, ensuring certainty for tax planning and financial reporting. This legal priority given to the refund minimizes the risk that administrative or budgetary pressures could lead to the deferral of the credit benefit.

C. Current Application of the 15-Year Carryforward Period

Although the 15-year CFP is operationally inert for new, refundable credits, it retains relevance in specific administrative and historical contexts:

• Legacy Credit Management: The 15-year CFP remains essential for tracking any non-refundable credit balances generated during the 2016 tax year and earlier. Taxpayers holding these credits must track the amortization of this deferred tax asset until it is fully utilized or until the statutory 15-year expiration date is reached (e.g., a 2016 credit would expire in 2031).
• Administrative Record Keeping: The Division of Revenue forms and instructions often include lines for tracking credit carryforwards.11 This infrastructure is required to handle legacy R&D credits as well as carryforward provisions for other state tax credits that may not be refundable.
• Maximum Utilization Window: In a general sense, the 15-year period defines the maximum allowable life of the tax credit from its year of generation. While the immediate refund negates the need for deferral, the period defines the longest possible time a company could defer utilization.

It must also be noted that Delaware, unlike the federal regime, explicitly allows no carryback of the R&D tax credit, regardless of the year generated.2

IV. Delaware Division of Revenue (DOR) Administrative Guidance

Compliance with the Delaware Division of Revenue’s administrative requirements is mandatory to secure the credit and its disposition.

A. Compliance Procedures and Documentation

The DOR requires an annual application process, detailed on its forms and instructions:

• Annual Application: Taxpayers must apply for the credit each year by submitting Form 2070AC (Research and Development Tax Credit Application).2
• Filing Deadline: The application deadline is strictly September 15th following the end of the taxable year in which the qualified research expenses were made.2
• Federal Requirement: To qualify for the Delaware credit, a taxpayer must file or be eligible to file for the corresponding federal R&D tax credit.4 A copy of the federal research credit, Form 6765 (Credit for Increasing Research Activities), must be attached to the Delaware application.2
• Finalization: Upon approval, the approved credit amount from Form 2070AC is transferred to Form 700, the Delaware Income Tax Credit Schedule, which is then attached to the taxpayer’s annual Delaware corporate income tax return.2

B. The Credit Schedule and Disposition Priority

Form 700 is the mechanism through which the credit is ultimately applied and utilized.

The sequence of credit utilization is crucial:

1. The approved credit amount is first applied against the taxpayer’s qualified tax liability for the taxable year.5
2. Any resulting credit amount that is deemed “unused” (i.e., exceeding the current year liability) is then subject to the mandate of $\S 2070(c)$ and processed as a cash tax refund.5
3. Because the unused portion is paid out in cash, the balance that would typically be carried forward for 15 years is reduced to zero.

Delaware’s administrative structure, including the inclusion of a line item for “Credit carryover from previous year” on Form 700 11, primarily facilitates the tracking of legacy non-refundable balances, not the disposition of new credits.

C. The Timing Constraint of the Application Deadline

The strict September 15th application deadline is a critical element of risk management for corporate tax departments. While federal law often allows businesses up to three years (the statute of limitations) to retroactively calculate and claim missed R&D credits 13, the Delaware application for the corresponding state credit must have been filed by the September 15th following the tax year.2

For example, if a company retrospectively identifies qualified R&D expenses for the 2021 tax year in 2024, they may amend their federal return (Form 6765) to claim the federal credit. However, the window to file the Delaware Form 2070AC for the 2021 tax year closed on September 15, 2022. If the application was missed, the opportunity to claim the lucrative state credit, with its immediate cash refund benefit, is forfeited, even if the federal claim is valid. This emphasizes that compliance with the application deadlines takes precedence over the eventual friendly disposition mechanism.

V. Strategic Disposition Matrix: Refund vs. Carryforward Utility

The strategic decision regarding the R&D credit benefit hinges entirely on the credit’s vintage. The following table illustrates the operational difference between the current regime and the legacy requirement that necessitated the 15-year carryforward.

Delaware R&D Credit Disposition Options and Strategy

VI. Financial Modeling Example: The Refundability Advantage

The true financial significance of Delaware’s current law—and the functional irrelevance of the 15-year CFP for new credits—is best demonstrated through a comparison of capital realization timing.

A. Scenario Setup: Innovate DE (Small Business)

• Entity Profile: Innovate DE, a Delaware C-Corporation, is a technology company with average annual gross receipts of $10 million.6 It qualifies for the small business enhancement (100% ASC rate).
• Year 1 R&D Investment: $1,500,000 in Delaware QREs.
• Credit Generated: The company calculates an approved Delaware R&D Tax Credit of $\mathbf{\$ 150,000}$.
• Year 1 Financials: The company is pre-profitability, reporting an NOL.

• Year 1 Delaware Corporate Tax Liability: $\mathbf{\$ 0}$.

B. The Utilization Outcomes

C. Financial and Strategic Implications

The distinction between these two scenarios is profound for financial management. In the Delaware model, Innovate DE secures an immediate influx of $\$150,000$ in cash during Year 1, providing crucial non-dilutive capital.14 This immediate realization reduces the dependency on external funding and accelerates the timeline for R&D expansion.

Conversely, in the traditional state, the $\$150,000$ R&D credit is classified on the balance sheet as a Deferred Tax Asset (DTA). The company must manage the credit over a potentially long 15-year horizon, assuming the risk that future tax liabilities materialize quickly enough to fully utilize the balance before the expiration date.

The mandatory cash refund has a direct positive impact on financial reporting under Generally Accepted Accounting Principles (GAAP) or International Financial Reporting Standards (IFRS). A traditional DTA requires management to assess the realization probability and often establish a valuation allowance if future profitability is uncertain. A refundable credit, however, can often be recorded as an immediate cash benefit or a direct reduction of income tax expense in the period generated, simplifying accounting procedures and providing greater certainty to investors and auditors regarding the true value of the incentive. The state’s decision to mandate the refund mechanism removes the inherent uncertainty and valuation risk associated with the long-term, 15-year carryforward of a non-refundable DTA.

VII. Conclusion and Recommendations

The Delaware R&D Tax Credit program is structured as a powerful, liquid incentive where the 15-year Carryforward Period serves primarily as a historical marker or a legal maximum lifespan, rather than a practical utilization mechanism for modern credits. This is driven entirely by the legislative mandate requiring the Division of Revenue to refund any unused portion of the approved credit.

A. Synthesis of Nuanced Conclusions

1. Refundability Dominates Disposition: For R&D credits generated in tax years beginning after 2016, the statutory provision in $\S 2070(c)$ dictates immediate cash disposition of any unused amount.5 This mandatory refund replaces the strategic need for the 15-year carryforward, maximizing the benefit for early-stage and pre-revenue companies.
2. Compliance Timeliness is Critical: The existence of the valuable, refundable credit is entirely dependent upon the timely submission of Form 2070AC by the September 15th deadline.2 Failure to meet this administrative deadline precludes the claim of the state credit, regardless of the taxpayer’s ability to claim the federal R&D credit retroactively.
3. The Carryforward Period as a Legacy Tool: The 15-year carryforward remains relevant only for managing residual, non-refundable credit balances generated prior to the 2017 legislative reforms.7 It also serves as the codified maximum statutory life for the incentive, in the event future legislation were to revert the credit to a non-refundable status.

B. Actionable Recommendations

For CFOs and Corporate Tax Directors managing Delaware tax liability:

• Financial Modeling: Companies should incorporate the R&D tax credit as an anticipated cash receipt in their working capital forecasts, rather than classifying it solely as a deferred tax asset, reflecting the mandatory refundability status.
• Compliance Review: An annual compliance audit should prioritize confirming the timely filing of Form 2070AC (by Sept 15th) and the required attachment of Federal Form 6765.4 The application process is the gateway to the financial benefit.
• Legacy Tracking: If a company holds R&D credits generated before 2017, stringent tracking must be maintained using Delaware Form 700 to ensure utilization occurs within the applicable 15-year carryforward window, as these older credits are non-refundable and subject to expiration.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/